Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
An eye on how patients perceive their retinal diseases
(Image credit: ©De Visu/AdobeStock) A recent study identified a large disconnect between patients with neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME) who are treated with intravitreal injections. The survey results highlighted the significant treatment burden experienced by…
First time results of VOY-101 for geographic atrophy
Omer Trivizki, MD, MBA, at the 2025 ASRS meeting Omer Trivizki, MD, MBA, Deputy Chair working in Tel Aviv Medical Center presented, “First time results of VOY-101, a novel, complement-modulating gene therapy for geographic atrophy.” This presentation was given at…
First patients dosed in JC02-88 study
(Image credit: ©Alernon77/AdobeStock) jCyte recently announced the dosing of the first patients enrolled in the JC02-88 study for the evaluation of famzeretcel (jCell; jCyte) for the treatment of retinitis pigmentosa (RP).1 Famzeretcel consists of allogeneic retinal progenitor cells (RPCs) administered…
Oluwatosin U. Smith, MD, previews a program of collaborative care and practical learning
Educational committee member Oluwatosin U. Smith, MD, highlights the 2025 Ophthalmology Times EyeCon® and Optometry Times EyeCon® conference, a multispecialty meeting for ophthalmologists and optometrists, highlighting program updates, collaborative learning opportunities, and evolving approaches in patient care. To learn more…
A large language model digital patient system enhances ophthalmology history taking skills | npj Digital Medicine – Nature
A large language model digital patient system enhances ophthalmology history taking skills | npj Digital Medicine Nature Source: Author: | Date: 2025-08-04 07:00:00 Source: Author: | Date: 2025-08-04 07:00:00
Evaluation of a simulation-based ophthalmology education workshop for medical students: a pilot project – BMC Medical Education
Evaluation of a simulation-based ophthalmology education workshop for medical students: a pilot project BMC Medical Education Source: Author: | Date: 2025-01-30 08:00:00 Source: Author: | Date: 2025-01-30 08:00:00
Glaukos Submits FDA Application for Epioxa Therapy
Glaukos Corporation has officially submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its innovative corneal cross-linking therapy, Epioxa (Epi-on). This next-generation treatment is designed for patients with keratoconus and represents a significant advancement…
Sepul Bio Launches Ultevursen Phase 2b Trial for RP
Sepul Bio has announced the dosing of the first patient in the LUNA clinical study, a Phase 2b trial evaluating ultevursen for the treatment of USH2A-associated retinitis pigmentosa (RP). This milestone represents renewed hope for individuals affected by this debilitating…
EYLEA HD Succeeds in Phase 3 RVO Trial
Regeneron Pharmaceuticals has announced that its Phase 3 QUASAR trial evaluating EYLEA HD (aflibercept 8 mg) has met its primary endpoint, marking a significant advancement in the treatment of retinal vein occlusion (RVO). About the QUASAR Trial The QUASAR trial…
Aurion’s AURN001 Shows Positive Phase 1/2 Results
Aurion Biotech has released topline data from its Phase 1/2 clinical trial (CLARA), evaluating AURN001, an allogeneic cell therapy product candidate for treating corneal edema secondary to corneal endothelial dysfunction. These results highlight the therapy’s potential as a groundbreaking treatment…